Seattle Genetics Reports Multiple Results of Adcetris (Brentuximab Vedotin) in P-III ECHELON-1, P-I/II, P-II and P-III AETHERA study in Patients with Hodgkin Lymphoma at ISHL 2018

 Seattle Genetics Reports Multiple Results of Adcetris (Brentuximab Vedotin) in P-III ECHELON-1, P-I/II, P-II and P-III AETHERA study in Patients with Hodgkin Lymphoma at ISHL 2018

Seattle Genetics Reports Multiple Results of Adcetris (Brentuximab Vedotin) in P-III ECHELON-1, P-I/II, P-II and P-III AETHERA study in Patients with Hodgkin Lymphoma at ISHL 2018

Shots:

  • The Multiple Studies P-III ECHELON-1 (Adcetris + CT vs CT), P-I/II & P-II (Adcetris + Opdivo(nivolumab)) and P-III AETHERA (Adcetris) is evaluated in patients with stage III or IV HL, r/r HL and HL at Risk of Relapse or Progression respectively
  • Results of P-III ECHELON-1: superior PFS with safety and efficacy: P-I/II & P-II: objective response, CR, PR (80%,82%; 61%, 55%; 20%,27%); OS & PFS (95%, 82%); IRR 36%: P-III AETHERA study: PFS rate (59% vs 41%); received anti-cancer therapy (32% vs 54%); allogeneic stem-cell transplants (17% vs 31%)
  • Adcetris is a ADC directed for CD30 and is currently evaluated in > 50 ongoing trials for HL. In 2018, Adcetris + CT received the US FDA approval for Stage III or IV HL in adults

Click here to read full press release/ article | Ref: Seattle Genetics | Image: The Street

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post